Improved glycaemic control in patients with type 2 diabetes has a beneficial impact on NAFLD, independent of change in BMI or glucose lowering agent. (2023)
Attributed to:
Dissecting the steroid metabolome in the pathogenesis and treatment of metabolic liver disease
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.numecd.2022.12.010
PubMed Identifier: 36710114
Publication URI: http://europepmc.org/abstract/MED/36710114
Type: Journal Article/Review
Volume: 33
Parent Publication: Nutrition, metabolism, and cardiovascular diseases : NMCD
Issue: 3
ISSN: 0939-4753